Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CING NASDAQ:KROS NASDAQ:RNA NASDAQ:RNAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$4.88+21.1%$5.25$3.16▼$11.89$54.28M-0.85817,015 shs1.11 million shsKROSKeros Therapeutics$10.50-0.5%$11.36$9.79▼$22.55$208.80M0.94333,783 shs190,460 shsRNAAvidity Biosciences$12.17-0.7%$13.27$11.95▼$16.77$208.18M0.93554,834 shs150,062 shsRNACCartesian Therapeutics$6.26-2.3%$6.80$5.60▼$15.57$188.34M0.66166,299 shs172,079 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate+21.09%+23.23%-9.12%-25.61%+22.61%KROSKeros Therapeutics-0.47%-7.16%-8.62%-10.33%-29.77%RNAAvidity Biosciences-0.65%-6.38%-9.25%-21.33%-64.63%RNACCartesian Therapeutics-2.34%-9.67%+0.64%-9.01%-36.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$4.88+21.1%$5.25$3.16▼$11.89$54.28M-0.85817,015 shs1.11 million shsKROSKeros Therapeutics$10.50-0.5%$11.36$9.79▼$22.55$208.80M0.94333,783 shs190,460 shsRNAAvidity Biosciences$12.17-0.7%$13.27$11.95▼$16.77$208.18M0.93554,834 shs150,062 shsRNACCartesian Therapeutics$6.26-2.3%$6.80$5.60▼$15.57$188.34M0.66166,299 shs172,079 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate+21.09%+23.23%-9.12%-25.61%+22.61%KROSKeros Therapeutics-0.47%-7.16%-8.62%-10.33%-29.77%RNAAvidity Biosciences-0.65%-6.38%-9.25%-21.33%-64.63%RNACCartesian Therapeutics-2.34%-9.67%+0.64%-9.01%-36.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate 2.50Moderate Buy$28.33480.60% UpsideKROSKeros Therapeutics 2.25Hold$20.4094.29% UpsideRNAAvidity Biosciences 2.37Hold$69.42470.43% UpsideRNACCartesian Therapeutics 2.67Moderate Buy$32.60420.77% UpsideCurrent Analyst Ratings BreakdownLatest CING, KROS, RNAC, and RNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.005/26/2026CINGCingulate HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.005/26/2026RNACCartesian Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$42.00 ➝ $40.005/22/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026RNAAvidity Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E-)5/19/2026CINGCingulate Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/15/2026KROSKeros Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/15/2026RNAAvidity Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/12/2026RNACCartesian Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.005/1/2026RNAAvidity Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/1/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A$0.31 per shareN/AKROSKeros Therapeutics$244.06M0.85$4.51 per share2.33$15.51 per share0.68RNAAvidity Biosciences$36.68M5.68N/AN/A$10.88 per share1.12RNACCartesian Therapeutics$2.80M65.69N/AN/A($4.85) per share-1.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$22.45M-$4.23N/AN/AN/AN/A-365.15%-158.55%8/18/2026 (Estimated)KROSKeros Therapeutics$87.01M-$3.01N/AN/AN/A-256.60%-17.04%-15.84%8/5/2026 (Estimated)RNAAvidity Biosciences-$322.30MN/AN/AN/AN/A-3,650.39%-44.92%-39.57%N/ARNACCartesian Therapeutics-$130.30M-$5.90N/AN/AN/A-8,550.65%N/A-28.25%8/6/2026 (Estimated)Latest CING, KROS, RNAC, and RNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CINGCingulate-$0.53-$0.95-$0.42-$0.95N/AN/A5/14/2026Q1 2026KROSKeros Therapeutics-$1.0229-$1.21-$0.1871-$1.21$1.93 million$0.37 million5/14/2026Q1 2026RNAAvidity Biosciences-$1.05-$0.97+$0.08-$0.97$2.00 million$19.64 million4/30/2026Q1 2026RNACCartesian Therapeutics-$0.84-$1.46-$0.62-$1.46$0.22 million$0.08 million3/18/2026Q4 2025CINGCingulate-$0.56-$0.84-$0.28-$0.84N/AN/A3/9/2026Q4 2025RNACCartesian Therapeutics-$0.82-$1.38-$0.56-$3.57$0.10 million$0.95 million3/4/2026Q4 2025KROSKeros Therapeutics-$0.49-$0.86-$0.37-$0.86$3.66 million$0.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulateN/A2.552.55KROSKeros TherapeuticsN/A22.6122.62RNAAvidity BiosciencesN/A9.2011.57RNACCartesian TherapeuticsN/A7.657.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%KROSKeros Therapeutics71.56%RNAAvidity BiosciencesN/ARNACCartesian Therapeutics86.95%Insider OwnershipCompanyInsider OwnershipCINGCingulate4.33%KROSKeros Therapeutics20.60%RNAAvidity Biosciences3.83%RNACCartesian Therapeutics37.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate2013.47 million12.89 millionNot OptionableKROSKeros Therapeutics10019.79 million15.72 millionOptionableRNAAvidity Biosciences19017.11 million149.21 millionOptionableRNACCartesian Therapeutics6429.38 million18.45 millionOptionableCING, KROS, RNAC, and RNA HeadlinesRecent News About These CompaniesCartesian Therapeutics (RNAC) Gets a Buy from WedbushMay 29, 2026 | theglobeandmail.comCartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027May 26, 2026 | globenewswire.comWe're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn RateMay 17, 2026 | finance.yahoo.comQ2 EPS Estimate for Cartesian Therapeutics Cut by AnalystMay 14, 2026 | marketbeat.comCartesian Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 12, 2026 | quiverquant.comQCartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 12, 2026 | globenewswire.comPrivium Fund Management B.V. Invests $1.24 Million in Cartesian Therapeutics, Inc. $RNACMay 6, 2026 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 4, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cartesian Therapeutics (RNAC) and Humana (HUM)May 2, 2026 | theglobeandmail.comCartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue EstimatesApril 30, 2026 | zacks.comCartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 30, 2026 | globenewswire.comCartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?April 20, 2026 | zacks.comCartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptApril 14, 2026 | seekingalpha.comCartesian Therapeutics Announces New Employment Inducement GrantsApril 2, 2026 | globenewswire.comCartesian Therapeutics (NASDAQ:RNAC) Stock, Short Interest ReportMarch 10, 2026 | benzinga.comCantor Fitzgerald upgrades Cartesian Therapeutics (RNAC)March 10, 2026 | msn.comCartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateMarch 9, 2026 | markets.businessinsider.comWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 8.15%February 18, 2026 | aaii.comACartesian Therapeutics Announces New Employment Inducement GrantsFebruary 3, 2026 | globenewswire.comCartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?January 14, 2026 | zacks.comCartesian Therapeutics Reports Progress in Phase 3 AURORA Trial of Descartes-08 for Myasthenia Gravis and Initiates Pediatric Trial for Juvenile DermatomyositisJanuary 9, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000By Jeffrey Neal Johnson | May 12, 2026Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30%By Leo Miller | May 6, 2026Vertical Aerospace: Pre-Flight Checks Point to a BreakoutBy Jeffrey Neal Johnson | May 20, 2026Micron’s $1 Trillion Memory Melt-UpBy Jeffrey Neal Johnson | May 27, 2026RTX Is Set to Revolutionize Munitions ManufacturingBy Jeffrey Neal Johnson | May 28, 2026CING, KROS, RNAC, and RNA Company DescriptionsCingulate NASDAQ:CING$4.88 +0.85 (+21.09%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$4.86 -0.02 (-0.51%) As of 05:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Keros Therapeutics NASDAQ:KROS$10.50 -0.05 (-0.47%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$10.50 0.00 (0.00%) As of 06/3/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Avidity Biosciences NASDAQ:RNA$12.17 -0.08 (-0.65%) As of 06/3/2026 04:00 PM EasternAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Cartesian Therapeutics NASDAQ:RNAC$6.26 -0.15 (-2.34%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$6.38 +0.12 (+1.93%) As of 06/3/2026 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
